JasonVBakerMDMS

Infectious Disease • Minneapolis, MN

HIV/AIDS Medicine

Director of Infectious Disease, Hennepin Healthcare | Professor of Medicine, University of Minnesota

Join to view full profile

Dr. Baker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baker's full profile

Already have an account?

Office
701 Park Ave
Mail Code G5
Minneapolis, MN 55415
Phone+1 612-873-2700

Fax+1 612-904-4440

Summary

Dr. Jason Baker is an infectious disease specialist in Minneapolis, MN and is affiliated with Hennepin Healthcare. He received his medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 16 years. He specializes in hiv/aids medicine and is experienced in cardiac manifestations of hiv infection, hiv/aids, and covid-19.

Education & Training

University of MinnesotaFellowship, Infectious Disease, 2004 - 2007
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2001 - 2004
University of Wisconsin School of Medicine & Public HealthClass of 2001

Certifications & Licensure

OR State Medical License 2003 - Present
MN State Medical License 2005 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

Clinical Trials

Aspirin and Antiretroviral Therapy in HIV Infected Patients Start of enrollment: 2008 Oct 01
Terminated
Phase 2
Cardiovascular Prevention for Persons With HIV Start of enrollment: 2009 Sep 01
Completed
Not Applicable
Artery Elasticity After Switch From Epzicom to Truvada Start of enrollment: 2009 Oct 01
Terminated
Phase 4
Respiratory Virus Hospitalization Study (FLU 003 Plus) Start of enrollment: 2009 Aug 01
Recruiting
Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START) Start of enrollment: 2009 Apr 15
Completed
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Start of enrollment: 2014 Sep 01
Completed
Phase 2
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial Start of enrollment: 2014 Oct 16
Completed
Phase 2
Optimization of a Behavioral Intervention to Increase Physical Activity in Older Adults Living With HIV Start of enrollment: 2023 Jun 21
Recruiting
Not Applicable
Lactoferrin Treatment in HIV Patients Start of enrollment: 2014 Sep 01
Completed
Phase 2
Outpatient Treatment With Anti-Coronavirus Immunoglobulin Start of enrollment: 2021 Aug 06
Recruiting
Phase 3
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial Start of enrollment: 2023 Jul 06
Recruiting
Phase 4
Engaging HIV Patients in Primary Care by Promoting Acceptance Start of enrollment: 2013 Mar 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Sexual Racism on Geosocial Networking Applications and Identity Outness Among Sexual Minority Men in the US.
Junye Ma, Dafna Paltin, Michael Miller-Perusse, Ashley Black, Jason V Baker
Journal of Homosexuality. 2025-01-28
Impact of Baseline SARS-CoV-2 Load in Plasma and Upper Airways on the Incidence of Acute Extrapulmonary Complications of COVID-19: A Multicentric, Prospective, Cohort ...
Tomas O Jensen, Katrina Harper, Shaili Gupta, Sean T Liu, Nila J Dharan
Clinical Infectious Diseases. 2024-12-17
Health Care Service Utilization Among People with HIV, Chronic Pain, and Depression: Utilization and Cost Outcomes from the HIV-PASS Study.
Ethan Moitra, Michael D Stein, Andrew M Busch, Megan M Pinkston, Jeremy W Bray
AIDS and Behavior. 2024-11-15

Press Mentions

NIH Study Evaluating Shionogi Antiviral in Hospitalized People with COVID-19February 15th, 2023
NIH Trial to Evaluate Shionogi Antiviral in Adults Hospitalized with COVID-19February 15th, 2023
A National Institutes of Health Trial Evaluating Shionogi Interferon in Adults Hospitalized with COVID-19February 15th, 2023

Professional Memberships

American College of Physicians - ACP
Member